4th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress (Time Zone - GREENWHICH MEAN TIME(GMT))

29th - 30th October, 2020

40+

Speakers

10+

Networking Hours

12+

Sessions

200+

Attendees

EVENT OVERVIEW

In the past decade, many scientific breakthroughs have been achieved through research including success in recent years of cancer immunotherapy with monoclonal antibodies, cancer vaccines, adoptive cell therapy and immune-checkpoint therapy. Personalized immunotherapy with various combinations will be the next promising strategy for the future cancer treatment direction.

Tag Line
30+ experts from academia and industry will be presenting their current work in Immuno-Oncology, Latest updates on regulatory guidelines and approvals, Validation markers for tumor-derived T-cell subpopulations, NextGen T-Cell and CAR-T Cell therapy, Personalized Medicine, Biomarkers and Cancer Immunotherapy
Tag Line
Opportunity to develop long-lasting business relationships and networking opportunities with researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies, Universities, and Research institutes.
Tag Line
Over 20 presentations, round-tables, and panel discussions focused on the key opportunities and challenges in biomarker research, Validation methods and innovative tools in IO Discovery, Oral T-Cell Therapies for the Treatment of Cancer Patients and Discovery of novel bispecific antibody molecules to boost anti-tumor immunity

Our 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress to be held on 29th - 30th October 2020 would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors. This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.

WHAT TO EXPECT

  • Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
  • Find out new case studies of immune-oncology projects in development
  • Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
  • Explore the latest platforms and technologies on the market for development
  • Discuss the best tool for your research in immune-oncology
  • Share your work and achievements with your industry peers in the Poster Sessions 

  • Updates in development of monoclonal antibodies, ADC’s and Bispecific Ab’s
  • Immune Checkpoint Inhibitors and Combinations
  • Biomarkers and Cancer Vaccines
  • CAR-T cell therapy, T Cell Therapy
  • Tumor microenvironment
  • Oncolytic Viruses
  • Microbiome in Cancer Immunotherapy

Expression #1 of SELECT list is not in GROUP BY clause and contains nonaggregated column 'cnceventswithcrm.s.id' which is not functionally dependent on columns in GROUP BY clause; this is incompatible with sql_mode=only_full_group_by